Lexeo’s gene therapy shows promising phase 1/2 results for Friedreich's ataxia cardiomyopathy 16-Jul-2024 By Helen Albert A gene therapy being developed by Lexeo Therapeutics to treat cardiomyopathy caused by Friedreich ataxia, a rare neurodegenerative genetic disease, has achieved good interim results in a phase 1/2 trial.